Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Somedeb Ball, Michael T. Byrne, Melissa A Fischer, Farrukh T. Awan, Ben K. Tomlinson, Tess Stopczynski, Lokesh Patil, Christine J. Gu, Chris Leonardi, Katherine J. Walsh, Gregory Dan Ayers, Ashwin Kishtagari, Kateryna Fedorov, Markus D. Lacher, Joseph Wagner, Sanjay R Mohan, Michael R. Savona

Blood (2024) 144 (Supplement 1): 6012.

https://doi.org/10.1182/blood-2024-209403

Published: 2024

Journal Articles

Treatment Patterns and Attitudes Among US-Based Physicians in Using BTK Inhibitors to Treat Relapsed/Refractory CLL and MCL

Ryan P. Topping, Timothy A. Quill, Farrukh T. Awan, Jonathon B. Cohen

Blood (2024) 144 (Supplement 1): 7601.

https://doi.org/10.1182/blood-2024-208406

Published: 2024

Journal Articles

A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies

Michael T. Tees, David A. Bond, Nadia Khan, Farrukh T. Awan, Qiming Xu, Hui Zhang, Gladys Brown, Jennifer A. Woyach, Manish Patel

Blood (2024) 144 (Supplement 1): 4422.1.

https://doi.org/10.1182/blood-2024-194009

Published: 2024

Journal Articles

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Alan P Skarbnik, Alexey V. Danilov, Marc Hoffmann, Farrukh T. Awan, Frank Scarpa, Caryn Davies, Todd Oakland, Marina Kovach, Jenna Lilyquist, Veerendra Munugalavadla, Alan SM Yong, Vikram Shetty, John N. Allan, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2024-209590

Published: 2024

Journal Articles

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 68.

https://doi.org/10.1182/blood-2024-208539

Published: 2024

Journal Articles

Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)

Farrukh T. Awan, Ran Liu, Hsin-Hui Huang, Matthew Bye, Kwang Wooahn, Gabriel S. Krigsfeld, Anat Raz, Heather R Wolfe, Mehdi Hamadani

Blood (2024) 144 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2024-194156

Published: 2024

Journal Articles

Enrollment in Clinical Trials Demonstrates Benefit for Low Income DLBCL Patients; A Retrospective National Cancer Database (NCDB) Analysis

William Schwartzman, Ang Gao, Chul Ahn, Heather R Wolfe, Praveen Ramakrishnan Geethakumari, Farrukh T. Awan, Elif Yilmaz

Blood (2024) 144 (Supplement 1): 5096.

https://doi.org/10.1182/blood-2024-210009

Published: 2024

Journal Articles

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Blood (2024) 144 (Supplement 1): 883.

https://doi.org/10.1182/blood-2024-199708

Published: 2024

Journal Articles

Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Sharlene Dong, Heather Reves, Yu-Lun Liu, Radhika Kainthla, Aimaz Afrough, Julio Alvarenga, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Adeel Khan, Kiran Achut Kumar, Yazan F. Madanat, Heather R Wolfe, Elif Yilmaz, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari

Blood (2023) 142 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2023-188033

Published: 2023

Journal Articles

The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US)

Farrukh T. Awan, Aleksandra Vidisheva, Matia Saeedian, Murat Kurt, Simran K. Tiwana, Masoom Priyadarshini

Blood (2023) 142 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2023-178058

Published: 2023

Journal Articles

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2023-184345

Published: 2023

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Geoffrey P. Shouse, Kristie A. Blum, Julie E. Haydu, Jeremy S. Abramson, Mayur Narkhede, Andrew Ip, Jennifer S. Michaelson, Patrick A. Baeuerle, Kristan Meetze, Irina Shapiro, Todd Shearer, Judith Inumerable, Jeff Jones, Farrukh T. Awan

Blood (2023) 142 (Supplement 1): 3142.

https://doi.org/10.1182/blood-2023-181239

Published: 2023

Journal Articles

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Steven M. Bair, Mayur Narkhede, Zachary AK Frosch, Elise A. Chong, Daniel A. Ermann, Iris Isufi, Farrukh T. Awan, Julio C Chavez, Grace N Bosma, Diana Abbott

Blood (2023) 142 (Supplement 1): 68.

https://doi.org/10.1182/blood-2023-187113

Published: 2023

Journal Articles

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Blood (2023) 142 (Supplement 1): 382.

https://doi.org/10.1182/blood-2023-182389

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 6921.

https://doi.org/10.1182/blood-2023-186596

Published: 2023

Journal Articles

Exploring Regional Challenges and Solutions to Appropriate and Equitable Care for Patients with Chronic Lymphocytic Leukemia

Farrukh T. Awan, Javier L. Munoz, Amy Goodrich, Onyemaechi Okolo-Taku, Christopher D'Andrea, Alison Mayer Sachs, Ashley Lile, Rania Emara, Lilly Meier, Elana Plotkin, Leigh Boehmer

Blood (2023) 142 (Supplement 1): 7253.

https://doi.org/10.1182/blood-2023-179917

Published: 2023

Journal Articles

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

Farrukh T. Awan, November McGarvey, Abraham Lee, Ken Imanak, Simran K. Tiwana, Sean Garrison, Masoom Priyadarshini

Blood (2023) 142 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2023-178048

Published: 2023

Journal Articles

Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) As Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas

Tanooha Veeramachaneni, Xingzhe Li, Neil Desai, Heather R Wolfe, Elif Yilmaz, Farrukh T. Awan, Robert H. Collins, Robert Timmerman, Praveen Ramakrishnan Geethakumari, Kiran Achut Kumar

Blood (2023) 142 (Supplement 1): 6283.

https://doi.org/10.1182/blood-2023-191089

Published: 2023

Journal Articles

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Farrukh T. Awan, Gaurav A. Deshpande, Trong Kim Le, Sean Garrison, Simran K. Tiwana, Masoom Priyadarshini

Blood (2022) 140 (Supplement 1): 7028–7029.

https://doi.org/10.1182/blood-2022-159195

Published: 2022

NARROW

Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Treatment Patterns and Attitudes Among US-Based Physicians in Using BTK Inhibitors to Treat Relapsed/Refractory CLL and MCL

A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)

Enrollment in Clinical Trials Demonstrates Benefit for Low Income DLBCL Patients; A Retrospective National Cancer Database (NCDB) Analysis

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US)

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Exploring Regional Challenges and Solutions to Appropriate and Equitable Care for Patients with Chronic Lymphocytic Leukemia

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) As Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only